Enhancing our understanding of the time course of acute exacerbations of COPD managed on an outpatient basis

International Journal of COPD

Volumn 13, Issue , 2018, Pages 3759-3766

  Oliveira, Ana ^a,b   Afreixo, Vera ^b,c   Marques, Alda ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF AVEIRO   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

COPD exacerbations; Management; Outcome measures; Outpatients

Indexed keywords

5 TIMES SIT TO STAND TEST; ADULT; AGED; ARTICLE; BODY MASS; CHARLSON COMORBIDITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CONVALESCENCE; COPD ASSESSMENT TEST; DISEASE COURSE; DISEASE EXACERBATION; DYSPNEA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; HUMAN; LONGITUDINAL STUDY; MALE; MAXIMAL INSPIRATORY PRESSURE; MODIFIED BRITISH MEDICAL RESEARCH COUNCIL QUESTIONNAIRE; MORBIDITY; MUSCLE STRENGTH; OBESITY; OBSERVATIONAL STUDY; OUTPATIENT; OUTPATIENT CARE; OXYGEN SATURATION; PERSONALIZED MEDICINE; QUADRICEPS FEMORIS MUSCLE; RESPIRATORY TRACT DISEASE ASSESSMENT; UNDERWEIGHT; AMBULATORY CARE; BLOOD GAS ANALYSIS; COMBINATION DRUG THERAPY; DRUG EFFECT; EXERCISE TEST; FITNESS; HEALTH STATUS; LUNG; MAXIMAL RESPIRATORY PRESSURE; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; QUESTIONNAIRE; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AMBULATORY CARE; BLOOD GAS ANALYSIS; BODY MASS INDEX; BRONCHODILATOR AGENTS; COMORBIDITY; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; LONGITUDINAL STUDIES; LUNG; MALE; MAXIMAL RESPIRATORY PRESSURES; MIDDLE AGED; MUSCARINIC ANTAGONISTS; MUSCLE STRENGTH; PHYSICAL FITNESS; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUADRICEPS MUSCLE; RECOVERY OF FUNCTION; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85058474092     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S175890     Document Type: Article

References (41)

1. Gulati S, Wells JM. Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators. Drugs. 2017;77(6):651–670.
2. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev. 2010; 19(116):113–118.
3. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2013;23(6):932–946.
4. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–245.
5. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003;58(9):752–756.
6. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157(5 Pt 1):1418–1422.
7. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(5): 1608–1613.
8. Parker CM, Voduc N, Aaron SD, Webb KA, O’Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J. 2005;26(3):420–428.
9. Koutsokera A, Kiropoulos TS, Nikoulis DJ, et al. Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir Med. 2009;103(6):919–926.
10. Feliz-Rodriguez D, Zudaire S, Carpio C, et al. Evolution of the COPD Assessment Test score during chronic obstructive pulmonary disease exacerbations: determinants and prognostic value. Can Respir J. 2013; 20(5):e92–e97.
11. Mesquita R, Donária L, Genz IC, Pitta F, Probst VS. Respiratory muscle strength during and after hospitalization for COPD exacerbation. Respir Care. 2013;58(12):2142–2149.
12. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2018. Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS. pdf. Accessed March 2, 2018.
13. Singanayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10(2):81–89.
14. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000;117(5):1345–1352.
15. Bildt C, Alfredsson L, Punnett L, Theobald H, Torgén M, Wikman A. Effects of drop out in a longitudinal study of musculoskeletal disorders. Occup Environ Med. 2001;58(3):194–199.
16. Søyseth V, Johnsen HL, Kongerud J. Prediction of dropout from respiratory symptoms and airflow limitation in a longitudinal respiratory study. Scand J Work Environ Health. 2008;34(3):224–229.
17. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
18. Doherty DE, Belfer MH, Brunton SA, Fromer L, Morris CM, Snader TC. Chronic obstructive pulmonary disease: consensus recommendations for early diagnosis and treatment. J Fam Pract. 2006;55(11):S1.
19. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
20. American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002;166(4):518–624.
21. Troosters T, Probst VS, Crul T, et al. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(10):1072–1077.
22. Bohannon RW. Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years. Arch Phys Med Rehabil. 1997;78(1):26–32.
23. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654.
24. Jones SE, Kon SS, Canavan JL, et al. The five-repetition sit-to-stand test as a functional outcome measure in COPD. Thorax. 2013; 68(11):1015–1020.
25. Ma Y, Mazumdar M, Memtsoudis SG. Beyond repeated-measures analysis of variance: advanced statistical methods for the analysis of longitudinal data in anesthesia research. Reg Anesth Pain Med. 2012; 37(1):99–105.
26. World Health Organization [homepage on the Internet]. BMI classification; 2006. Available from: http://apps.who.int/bmi/index. jsp?introPage=intro_3.html. Accessed May 24, 2018.
27. Spruit MA, Augustin IM, Vanfleteren LE, et al. Differential response to pulmonary rehabilitation in COPD: multidimensional profiling. Eur Respir J. 2015;46(6):1625–1635.
28. Guerra B, Gaveikaite V, Bianchi C, Puhan MA. Prediction models for exacerbations in patients with COPD. Eur Respir Rev. 2017;26(143): 160061.
29. Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev. 2018;27(147):170103.
30. Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203.
31. Jones PW, Harding G, Wiklund I, et al. Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest. 2012;142(1):134–140.
32. García-Sidro P, Naval E, Martinez Rivera C, et al. The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations. Respir Med. 2015;109(12):1546–1552.
33. Miravitlles M, García-Sidro P, Fernández-Nistal A, Buendía MJ, Espinosa de Los Monteros MJ, Molina J. Course of COPD assessment test (CAT) and clinical COPD questionnaire (CCQ) scores during recovery from exacerbations of chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2013;11(1):147–149.
34. Al Rajeh AM, Hurst JR. Monitoring of Physiological Parameters to Predict Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review. J Clin Med. 2016;5(12):108–118.
35. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4): 347–365.
36. Eaton T, Young P, Fergusson W, et al. Does early pulmonary rehabilitation reduce acute health-care utilization in COPD patients admitted with an exacerbation? A randomized controlled study. Respirology. 2009;14(2):230–238.
37. Torres-Sánchez I, Valenza MC, Sáez-Roca G, Cabrera-Martos I, López-Torres I, Rodríguez-Torres J. Results of a Multimodal Program During Hospitalization in Obese COPD Exacerbated Patients. COPD. 2016;13(1):19–25.
38. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J. 1993; 6 Suppl 16:5–40.
39. Bernabeu-Mora R, Medina-Mirapeix F, Llamazares-Herrán E, Oliveira-Sousa SL, Sánchez-Martinez MP, Escolar-Reina P. The accuracy with which the 5 times sit-to-stand test, versus gait speed, can identify poor exercise tolerance in patients with COPD: A cross-sectional study. Medicine. 2016;95(35):e4740.
40. Wang Z, Bafadhel M, Haldar K, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J. 2016;47(4):1082–1092.
41. Wan ES. Examining genetic susceptibility in acute exacerbations of COPD. Thorax. 2018;73(6):507–509.